HCK is a Potential Prognostic Biomarker That Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Mar 14

PMID 35280440

Authors

Fang Cheng

Qiang Li

Jinglin Wang

Liu Wang

Weiming Li

Fang Zeng

Affiliations

Soon will be listed here.

Abstract

Background: The tumor microenvironment (TME) plays a significant role in the progression and prognosis of acute myeloid leukemia (AML). This study is aimed at exploring TME-associated biomarkers and identify their potential mechanism in the microenvironment of AML.

Method: In this study, the stromal, immune, and ESTIMATE scores of AML patients were evaluated with the ESTIMATE and CIBERSORT algorithms; then, the AML samples were divided into high- and low-score groups. We evaluated the association between clinicopathological characteristics, survival rate, and the stromal/immune/ESTIMATE scores. Furthermore, we identified TME-associated differentially expressed genes (DEGs) then carried out pathway enrichment analysis, protein-protein interaction (PPI) network, Cox regression analysis, and Kaplan-Meier survival analysis to select the most crucial genes. In addition, we further explored the potential mechanism of HCK in the AML microenvironment.

Results: We identified 624 TME-associated DEGs and found that HCK was the most promising biomarker associated with AML. The results of the gene set enrichment analysis (GSEA) indicated that HCK was mainly involved in immune and inflammation-related signaling pathways. In addition, CIBERSORT analysis showed that HCK was closely related to tumor immune infiltration, with HCK expression associated with various infiltrating immune cells, including B cells, T cells, tumor-associated macrophages (TAM), NK cells, plasma cells, eosinophils, and neutrophils. Furthermore, HCK expression was closely related with ELN risk stratification in patients with AML.

Conclusion: HCK could regulate immune cell infiltration in the microenvironment of AML and may act as a potential biomarker for the treatment and prognosis of AML patients.

Citing Articles

Comprehensive analysis of the HCK gene in myeloid neoplasms: Insights into biological functions, prognosis, and response to antineoplastic agents.

Carvalho M, de Almeida B, Bueno M, Vicari H, Lima K, Rego E Hematol Transfus Cell Ther. 2024; 46(3):273-282.

PMID: 38326180 PMC: 11221266. DOI: 10.1016/j.htct.2023.11.007.

Identification of key signaling pathways and hub genes related to immune infiltration in Kawasaki disease with resistance to intravenous immunoglobulin based on weighted gene co-expression network analysis.

Wang Y, Cao Y, Li Y, Yuan M, Xu J, Li J Front Mol Biosci. 2023; 10:1182512.

PMID: 37325483 PMC: 10267737. DOI: 10.3389/fmolb.2023.1182512.

Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression.

Zhang Q, Ma R, Chen H, Guo W, Li Z, Xu K J Oncol. 2023; 2023:9988405.

PMID: 37064861 PMC: 10104747. DOI: 10.1155/2023/9988405.

A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.

Lan Y, Jia Q, Feng M, Zhao P, Zhu M Front Genet. 2023; 14:1100020.

PMID: 37035749 PMC: 10076548. DOI: 10.3389/fgene.2023.1100020.

Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients.

Li Y, Liu Y, Duo M, Wu R, Jiang T, Li P Cell Commun Signal. 2022; 20(1):201.

PMID: 36575422 PMC: 9793391. DOI: 10.1186/s12964-022-01010-2.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Laskowska J, Lewandowska-Bieniek J, Szczepanek J, Styczynski J, Tretyn A . Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias. J Gene Med. 2016; 18(8):165-79. DOI: 10.1002/jgm.2889. View

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View

Huang S, Zhang B, Fan W, Zhao Q, Yang L, Xin W . Identification of prognostic genes in the acute myeloid leukemia microenvironment. Aging (Albany NY). 2019; 11(22):10557-10580. PMC: 6914404. DOI: 10.18632/aging.102477. View

Kovacs M, Nemeth T, Jakus Z, Sitaru C, Simon E, Futosi K . The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. J Exp Med. 2014; 211(10):1993-2011. PMC: 4172222. DOI: 10.1084/jem.20132496. View

Wang J, Hao J, Uddin M, Wu Y, Chen R, Li D . Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia. Aging (Albany NY). 2021; 13(12):16445-16470. PMC: 8266366. DOI: 10.18632/aging.203166. View

Anderson N, Simon M . The tumor microenvironment. Curr Biol. 2020; 30(16):R921-R925. PMC: 8194051. DOI: 10.1016/j.cub.2020.06.081. View

Chen B, Khodadoust M, Liu C, Newman A, Alizadeh A . Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018; 1711:243-259. PMC: 5895181. DOI: 10.1007/978-1-4939-7493-1_12. View

Poh A, Love C, Masson F, Preaudet A, Tsui C, Whitehead L . Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell. 2017; 31(4):563-575.e5. PMC: 5479329. DOI: 10.1016/j.ccell.2017.03.006. View

10.

Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, Soverini S . The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. Int J Mol Sci. 2021; 22(13). PMC: 8269413. DOI: 10.3390/ijms22136857. View

11.

Estey E . Acute myeloid leukemia: 2016 Update on risk-stratification and management. Am J Hematol. 2016; 91(8):824-46. DOI: 10.1002/ajh.24439. View

12.

Waldeck S, Rassner M, Keye P, Follo M, Herchenbach D, Endres C . CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML. Mol Oncol. 2020; 14(4):779-794. PMC: 7138400. DOI: 10.1002/1878-0261.12640. View

13.

Lantermans H, Minderman M, Kuil A, Kersten M, Pals S, Spaargaren M . Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. Leukemia. 2020; 35(3):881-886. PMC: 7932922. DOI: 10.1038/s41375-020-0934-6. View

14.

Bader J, Voss K, Rathmell J . Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020; 78(6):1019-1033. PMC: 7339967. DOI: 10.1016/j.molcel.2020.05.034. View

15.

Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y . CCR5 Directs the Mobilization of CD11bGr1Ly6C Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. Cell Rep. 2017; 21(8):2212-2222. DOI: 10.1016/j.celrep.2017.10.104. View

16.

Poh A, ODonoghue R, Ernst M . Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget. 2015; 6(18):15752-71. PMC: 4599235. DOI: 10.18632/oncotarget.4199. View

17.

Ernst M, Inglese M, Scholz G, Harder K, Clay F, Bozinovski S . Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response. J Exp Med. 2002; 196(5):589-604. PMC: 2193996. DOI: 10.1084/jem.20020873. View

18.

Creeden J, Alganem K, Imami A, Henkel N, Brunicardi F, Liu S . Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia. Int J Mol Sci. 2020; 21(22). PMC: 7700673. DOI: 10.3390/ijms21228823. View

19.

Liu X, Chen J, Munshi M, Hunter Z, Xu L, Kofides A . Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020; 4(1):141-153. PMC: 6960458. DOI: 10.1182/bloodadvances.2019000947. View

20.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View